 |
BenevolentAI
Last updated: January 22, 2024
Founder Ken Mulvany
Country: UK | Funding: $292M (+)
Website: http://benevolent.ai
BenevolentAI is applying artificial intelligence to develop new medicines for hard to treat diseases. It is the first fully integrated AI company with pharmaceutical discovery and clinical development capabilities. BenevolentAI’s advanced technology is disrupting the pharmaceutical industry by lowering costs, decreasing failure rates and increasing the speed at which medicines are delivered to patients.
Website: http://benevolent.ai
BenevolentAI is applying artificial intelligence to develop new medicines for hard to treat diseases. It is the first fully integrated AI company with pharmaceutical discovery and clinical development capabilities. BenevolentAI’s advanced technology is disrupting the pharmaceutical industry by lowering costs, decreasing failure rates and increasing the speed at which medicines are delivered to patients.
